[26/04, 08:02]hu2: Rather than PDF, cloud based full text URLs are a better way to share
[26/04, 08:04]hu2: Another journal article I was led to after I read the previous article:
Loved reading it. Thanks for sharing
[26/04, 08:15]hu1: When I did *critical appraisal* using both *CASP* (Case Report Checklist) and *JBI* Critical Appraisal Checklist for Case Reports formats.
This is the biggest issue.
👉 No method used (e.g., *Bradford Hill criteria*) to assess causality.
This report is *hypothesis-generating*, not practice-changing.
Ayurvedic treatment is described conceptually rather than practically.
It does NOT provide sufficient evidence to recommend Ayurvedic treatment as an alternative to standard prostate cancer care.
[26/04, 08:21]hu2: Agree with this. The authors too haven't claimed anything extra beyond this although perhaps adding the above would have made it better but then at this day and age AI agents would automatically do it anyways
Their value addition lies in sharing this information in a single patient where there was a prostatic carcinoma regression beyond doubt.
[26/04, 08:24]hu2: 👆It made me search into incidental T1 carcinoma which has been sparsely reported and appears to have considerable management uncertainty around it even in mainstream medicine!
[26/04, 08:27]hu1: This is really interesting to read.
[26/04, 08:28]hu1: Also I wanted to share one case I'm treating of Ductal Carcinoma
[26/04, 08:32]hu2: Here's more around current management uncertainty in T1 incidentally detected prostate carcinoma👇
[26/04, 10:58]hu1: This is a deeply problematic paper, and the problems are layered — from the clinical framing down to the mechanistic speculation. Here’s a systematic takedown.
1. The Central Flaw: They Chose the Most Indolent Cancer Possible
This is the single most damning issue and everything else follows from it.
The patient had Gleason 6 (3+3), T1, unifocal, 0.06 cm lesion, 1/2 cores positive, involving 2% of specimen. This is textbook very-low-risk prostate cancer — the category that the entire field of oncology spent the last two decades arguing is overtreated. The ProtecT trial, the Scandinavian Prostate Cancer Group trials, and the explosion of active surveillance literature exist precisely because Gleason 6 prostate cancer has an extremely indolent natural history and causes cancer-specific death in a small fraction of cases even without any treatment.
The authors are essentially claiming Ayurveda cured a cancer that routinely doesn’t progress, can stabilize spontaneously, and which modern guidelines would now manage with active surveillance — not radical prostatectomy. The framing of the patient “bravely refusing” prostatectomy is misleading; by current NCCN criteria, a patient with this exact profile would be offered active surveillance as the preferred approach.
The comparison to radiotherapy recurrence rates (10–30% at 5 years, 50–60% at 10 years) is a deliberate red herring — those figures apply to higher-risk disease receiving definitive radiation, not to very-low-risk T1 Gleason 6 managed conservatively.
2. The “Regression” Is Almost Certainly Biopsy Sampling Artifact
The initial diagnosis rested on 1 of 2 cores positive. That is vanishingly thin sampling. Standard prostate biopsy protocols use 10–12 systematic cores precisely because single-region sampling is unreliable. The follow-up biopsy showing benign hyperplasia in 12 cores is not surprising — the cancer lesion may never have been in the exact sampling zone again. This is the same problem that has driven the field toward MRI-targeted fusion biopsy: standard TRUS biopsy misses and over-represents based on sampling location.
The authors acknowledge biopsy limitations nowhere. The “confirmed regression” in a second biopsy is not confirmation — it’s replication of a low-sensitivity test.
3. The PSA Drop Doesn’t Implicate Ayurvedic Treatment
PSA fell from 11.2 to 3.9 ng/mL in 40 days. The paper attributes this to Chirivilwadi Kashayam. Consider the alternatives:
• The patient had a documented history of recurrent urinary infections. Post-infectious PSA elevation is well-established and can be dramatic. If the consultation or workup period coincided with resolution of a prostatitis episode, PSA normalization is entirely expected.
• The patient had BPH (enlarged prostate with nodules on DRE). BPH itself elevates PSA and varies with inflammation and urinary retention.
• There is no documented baseline infection workup, no C-reactive protein, no urine culture results reported.
The paper dismisses spontaneous remission with one sentence citing a lack of literature, then pivots to claiming the treatment caused the effect — without considering the most parsimonious explanation: the PSA was inflated by infection/inflammation, resolved on its own, and the cancer was always too small and Gleason-6 to drive the PSA meaningfully.
4. The Retrospective EPIC-CP Is Recall Bias, Not Data
The pre-treatment EPIC-CP quality-of-life questionnaire was “retrospectively evaluated in August 2011” — meaning the patient was asked to recall his symptoms from 2010. The post-treatment EPIC-CP was recorded in December 2011. This is not a validated pre-post comparison; it is a memory exercise. The improvement in sexual function (erections going from “not firm enough for any activity” to “firm enough for intercourse”) is particularly suspect — this is the domain most sensitive to expectation, placebo, and recall distortion. Reporting this as evidence of treatment efficacy is methodologically indefensible.
5. The Mechanistic Section Is In Vitro Speculation Dressed as Clinical Evidence
The “probable mode of activity” section is a standard Ayurvedic case report move: identify herb → find in vitro study showing some anticancer activity in a cell line → imply mechanism. Let’s be specific about what’s actually cited:
• Boerhavia diffusa inhibiting prostate growth in a rat BPH model at 100 mg/kg. Rat BPH models induced by testosterone do not translate to human prostate adenocarcinoma.
• Aegle marmelos inhibiting cancer cell lines in vitro. Cell line inhibition is not clinical efficacy.
• Tribulus terrestris extract showing 82.33% inhibition of MCF-7 breast cancer cells. This is cited as supporting its role in treating prostate cancer. No mechanistic bridge is offered.
• KSB (Karpura Silajathu Bhasma) rationalized via calcium nanoparticle studies using engineered calcium-manganese constructs. The leap from an Ayurvedic mineral preparation to cutting-edge nanomedicine immunotherapy is not a mechanistic argument; it is retrofitting.
• Guggulsterone on PC-3 cells — PC-3 is a castration-resistant, androgen-insensitive prostate cancer line. Completely different biology from the patient’s androgen-sensitive Gleason 6.
None of these studies constitute evidence that the prescribed formulations, at the doses given orally to this patient, achieved therapeutic drug levels at the prostate. The pharmacokinetic chain from “herb contains compound X → compound X does Y in a dish → therefore oral Kashayam treats prostate cancer” is broken at every link.
6. LLR Contains Rasa Sindura — Undisclosed Mercury
Laghu Lokeswara Rasa is a classical Rasa Shastra preparation in which Rasa Sindura (mercury sulfide, HgS) is the primary compound. The paper describes this as “a special preparation where a small quantity of Rasa Sindura is filled inside cowrie shells.” There is no safety discussion, no serum mercury monitoring reported, and no adverse drug reaction framework for a heavy metal compound given for 9 months. The authors report “no ADRs” as if this is reassuring, but without blood or urine heavy metal testing, this is just absence of reported symptoms, not safety data.
7. Conflict of Interest Is Structural, Not Declared
AS (the treating physician) conceived the study, analyzed the case, monitored the patient over 12 years, prepared the initial draft, and is presumably the lead author. The ethics statement says approval was not sought “as it describes standard clinical care.” Ayurvedic-only management of diagnosed prostate cancer, with active refusal of oncological evaluation, is not standard clinical care. This framing lets the authors sidestep IRB scrutiny on a potentially ethically fraught case (advising a cancer patient away from guideline-concordant treatment).
8. The 12-Year Follow-Up Is Not Validated
The claim of “cancer-free after 12 years” rests entirely on PSA remaining below 5 ng/mL. There is no mention of repeat imaging (no MRI prostate, no bone scan, no CT), no repeat biopsy after the 9-month confirmation. PSA stability in very-low-risk Gleason 6 is expected regardless of treatment — this is the entire basis of active surveillance programs. A PSA of 3.9 after 12 years in this patient profile would be unremarkable even with zero intervention.
9. The Conclusion Overreaches Dramatically
The abstract says “complete tumor regression with exclusive Ayurvedic treatment.” The conclusion calls Ayurveda “a promising approach to managing prostate cancer, offering prolonged survival.” Both claims are unsupported. What the paper actually shows is: a patient with very-low-risk prostate cancer declined surgery, took herbal formulations, had a PSA drop likely attributable to infection resolution, had a negative follow-up biopsy that is consistent with sampling variability, and remains alive 12 years later — exactly as most such patients do regardless of treatment.
Summary Assessment
This paper exemplifies the structural problem with Ayurvedic cancer case reports: they select the most favorable clinical scenario, attribute natural disease course or non-specific effects to the intervention, use in vitro mechanistic data as a clinical argument, and publish under a limitations section that is too brief to do the epistemic damage justice. The authors acknowledge the absence of RCTs in one sentence and then proceed to discuss “promising” outcomes as if this caveat excuses the inferential leap.
The paper should not have been published in its current form without requiring the authors to: (a) explicitly address Gleason 6 natural history and active surveillance equivalence; (b) discuss sampling error as the primary explanation for biopsy regression; (c) include mercury safety data for LLR; and (d) retract the “exclusive Ayurvedic treatment caused tumor regression” framing as unsupported by the evidence presented.
[26/04, 11:08]hu2: 👏
No comments:
Post a Comment